thx... looks like Sorafenib and Bavituximab trial canned due to lack of interest and Bavituximab With Radiation and Temozolomide has fully enrolled ahead of schedule per clinicaltrials.gov. The keytruda trial has not been updated recently.
Great post and thank you to everyone that went to the SM. I appreciate the update and like evrything I am seeing here. A year from now we will be profitable and the SP will reflect it. Also no telling how Oncologie may move forward over the next year. 2019/20 WAG we are at $20.00
Market Data 
Markets 
AI
